Sort
59,101 grants matching “hypertension”
Subcellular Distribution & Regulation of Ala1 Adrenoceptors
$432,845Debra A. Schwinn · University Of Washington · R37 · FY2010 · HL
The interleukin-1 receptor regulates crosstalk between myeloid and renal tubular cells in hypertension
$432,799Steven D Crowley · Duke University · R01 · FY2022 · DK
The interleukin-1 receptor regulates crosstalk between myeloid and renal tubular cells in hypertension
$432,799Steven D Crowley · Duke University · R01 · FY2021 · DK
The interleukin-1 receptor regulates crosstalk between myeloid and renal tubular cells in hypertension
$432,799Steven D Crowley · Duke University · R01 · FY2020 · DK
GENETIC DETERMINANTS OF CATARACT
$432,788Alan Shiels · Washington University · R01 · FY2014 · EY
Diabetes and Alzheimer's Disease
$432,761Lenore J Launer · National Institute On Aging · ZIA · FY2019 · AG
Targeting Sympathetic Overactivity in CKD patients: Mechanisms & Novel Therapies
$432,755Paul J Fadel · University Of Texas Arlington · R01 · FY2018 · HL
Development and evaluation of community-based approaches and donor care intervention models for improving availability and safety of blood for the management of severe anemia in Ghana
$432,737Yvonne Dei-Adomakoh · University Of Ghana · UH3 · FY2025 · HL
Multiphoton imaging of the juxtaglomerular apparatus
$432,737Janos Peti-Peterdi · University Of Southern California · R01 · FY2019 · DK
Multiphoton imaging of the juxtaglomerular apparatus
$432,737Janos Peti-Peterdi · University Of Southern California · R01 · FY2017 · DK
Genetic determinants of urine lithogenicity
$432,727John C Lieske · Mayo Clinic Rochester · R01 · FY2011 · DK
eNOS-Dependent Mechanoregulation of Intraocular Pressure
$432,721W Daniel Stamer · Duke University · R01 · FY2016 · EY
Pulmonary vascular-targeted NO therapeutic strategies
$432,711Mark Thomas Gladwin · University Of Pittsburgh At Pittsburgh · P01 · FY2013 · HL
Embolus extravasation: an alternative mechanism of microvascular recanalization
$432,702Jaime Grutzendler · Yale University · R01 · FY2012 · HL
Effectiveness of treat-to-target versus risk-based blood pressure guidelines
$432,679Andrew Edward Moran · Columbia University Health Sciences · R01 · FY2012 · HL
Effective Delivery of Pharmaceutical Aerosols during Non-Invasive Ventilation
$432,679P. Worth Longest · Virginia Commonwealth University · R01 · FY2014 · HL
Nutrition-Behavioral Cardiovascular Disease Prevention
$432,672Denise Ella Wilfley · Washington University · T32 · FY2011 · HL
AFRICAN AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSIO
$432,626Johns Hopkins University · U01 · FY2001 · DK
Animal model and resource development for preclinical lower urinary tract research
$432,625James Arthur Hokanson · Medical College Of Wisconsin · R21 · FY2025 · DK
Defining the mechanisms of lymphatic and lymphovenous valve development
$432,623Rajanarayanan S Srinivasan · Oklahoma Medical Research Foundation · R01 · FY2018 · HL
Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
$432,500Stephen Jae Kim · Vanderbilt University Medical Center · R01 · FY2024 · EY
Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
$432,500Stephen Jae Kim · Vanderbilt University Medical Center · R01 · FY2023 · EY
APOL1 variants: Understanding the basis of disparities in rates of kidney disease
$432,500Martin R. Pollak · Beth Israel Deaconess Medical Center · R01 · FY2020 · MD
Ocular Inflammatory Mediators in the Pathophysiology of Diabetic Retinopathy
$432,500Stephen Jae Kim · Vanderbilt University Medical Center · R01 · FY2020 · EY
Transcriptional Regulation by Angiotensin II in Vascular Smooth Muscle Cells
$432,500Rama Natarajan · Beckman Research Institute/City Of Hope · R01 · FY2019 · HL